Computational Screening of Marchantia polymorpha Against KRAS G12C Mutation in Non-Small Cell Lung Cancer

Merve Aras; Özlem Yayıntaş

doi:10.12991/jrespharm.1645818

Computational Screening of Marchantia polymorpha Against KRAS G12C Mutation in Non-Small Cell Lung Cancer

Abstract

Non-Small Cell Lung Cancer (NSCLC) constitutes approximately 85% of all lung cancer cases and is a leading cause of cancer-related mortality worldwide. Despite advances in cancer therapies, many current treatments are associated with severe side effects, complicating therapeutic protocols and adversely impacting patients’ quality of life. Recent in-silico studies have highlighted the potential of plant-derived phytochemicals as alternative therapeutic agents targeting genetic mutations implicated in cancer progression. In a prior study, we demonstrated the anticancer properties of Marchantia polymorpha L. extract on A549 cells. This study aims to discover small molecules that may act as inhibitors on KRAS G12C mutant protein from Marchantia polymorpha metabolites using in silico methods. The affinity value of Marchantia polymorpha L. secondary metabolites for the KRAS G12C mutated protein was determined by molecular docking analysis. Metabolites with high-affinity values and interacting with cysteine at position 12 were selected. Pharmacokinetic and toxicity studies of the selected metabolites were performed. All results were compared with the drug adagrasib and a plant-based small molecule that could be an inhibitor of the KRAS G12C mutation was discovered. Our computational analyses identified Rosmarinic Acid and Chlorogenic Acid, two natural compounds, as promising inhibitors of the KRAS G12C mutation. These compounds exhibited inhibitory efficacy comparable to Adagrasib, a clinically approved KRAS G12C inhibitor. Rosmarinic Acid and Chlorogenic Acid, with their favorable safety profiles and potential to inhibit KRAS G12C, represent promising natural and cost-effective alternatives for NSCLC treatment. Further experimental validation and clinical studies are warranted to explore their therapeutic potential.

Keywords

References

[1] Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non-small cell lung cancer: Past, present and future. World J Clin Oncol. 2021;12(4):217–237. https://doi.org/10.5306/wjco.v12.i4.217
[2] Asati V, Mahapatra D, Bharti S. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives. Eur J Med Chem. 2016;109:314-341. https://doi.org/10.1016/j.ejmech.2016.01.012
[3] Li Z, Zhao L, Yu L, Wei M. BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. Gastroenterol Rep. 2020;8(3):192-205. https://doi.org/10.1093/gastro/goaa022
[4] Liang F, Kang Z, Sun X, Chen J, Duan X, He H, Cheng J. Inhibition mechanism of MRTX1133 on KRASG12D: a molecular dynamics simulation and Markov state model study. J Comput Aided Mol Des. 2023;37:157–166. https://doi.org/10.1007/s10822-023-00498-1
[5] Tragulpakseerojn J, Yamaguchi N, Pamonsinlapatham P, Wetwitayaklung P, Yoneyama T, Ishikawa N, Ishibashi M, Apirakaramwong A . Anti-proliferative effect of Moringa oleifera Lam (Moringaceae) leaf extract on human colon cancer HCT116 cell line. Trop J Pharm Res. 2017;16(2):371-378. https://doi.org/10.4314/tjpr.v16i2.16
[6] Abbas S, Chang D, Riaz N, Maan AA, Khan MKI, Ahmad I, Alsagaby SA, El-Ghorab A, Ali M, Imran M, Ullah A, Mehmood T, Hyder MZ, Sajjad M, Umer M, Shabbir A, Afzal MI. In-vitro stress stability, digestibility and bioaccessibility of curcumin-loaded polymeric nanocapsules. J Exp Nanosci. 2021;16(1):229-245. https://doi.org/10.1080/17458080.2021.1952185
[7] Tonguç Yayıntaş O, Irkin LC. Bryophytes as Hidden Treasure. J Sci Perspect. 2018;2(1):71–83. https://doi.Org/10.26900/Jsp.2018.07
[8] Asakawa Y. Liverworts – potential source of medicinal compounds. Curr Pharm Design. 2008;14(29):3067–3088. https://doi.org/10.2174/138161208786404272

[9] Cianciullo P, Cimmino F, Maresca V, Sorbo S, Bontempo P, Basile A. Anti-tumour activities from secondary metabolites and their derivatives in Bryophytes: A brief review. Appl Biosci. 2022;1(1):73-94. https://doi.org/10.3390/applbiosci1010005
[10] Tonguç Yayıntaş O, Yılmaz S, Sökmen M. Determination of antioxidant, antimicrobial and antitumor activity of bryophytes from Mount Ida (Canakkale, Turkey). Indian J Tradit Knowl. 2019;18(2):395-401. http://nopr.niscpr.res.in/handle/123456789/47066
[11] Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23:3-25. https://doi.org/10.1016/S0169-409X(96)00423-1
[12] Chen K, Zhang Y, Qian L, Wang P. Emerging strategies to target RAS signaling in human cancer therapy. J Hematol Oncol. 2021;14:116. https://doi.org/10.1186/s13045-021-01127-w
[13] Addeo A, Banna GL, Friedlaender A. KRAS G12C Mutations in NSCLC: From Target to Resistance. Cancers (Basel). 2021;13(11):2541. https://doi.org/10.3390/cancers13112541
[14] Liu J, Kang R, Tang D. The KRAS-G12C inhibitor: Activity and resistance. Cancer Gene Ther. 2022;29:875–878. https://doi.org/10.1038/s41417-021-00383-9
[15] Lim TKH, Skoulidis F, Kerr KM, Ahn MJ, Kapp JR, Soares FA, Yatabe Y. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing. Lung Cancer. 2023;184: 107293. https://doi.org/10.1016/j.lungcan.2023.107293
[16] Foo B, Williamson B, Young JC, Lukacs G, Shrier A. hERG quality control and the long QT syndrome. J Physiol. 2016;594(9):2469–2481. https://doi.org/10.1113/JP270531
[17] FDA-Approved Drugs. (2025). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm (accessed on 03 January 2025)
[18] Adagrasib. (2025). https://go.drugbank.com/drugs/DB15568 (accessed on 03 January 2025)
[19] Liao XZ, Gao Y, Sun LL, Liu JH, Chen HR, Yu L, Chen ZZ, Chen WH, Lin LZ. Rosmarinic acid reverses non-small cell lung cancer cisplatin resistance by activating the MAPK signaling pathway. Phytother Res. 2020;34(5):1142-1153.https://doi.org/10.1002/ptr.6584
[20] Yuan Y, Jie L, Jia H, Ni H, Ying S, Leia D. Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases. Anti-Cancer Drugs. 2015;26(5):540-546. https://doi.org/10.1097/CAD.0000000000000218
[21] Wang J, Li G, Rui T, Kang A, Li G, Fu T, Li J, Di L, Cai B. Pharmacokinetics of rosmarinic acid in rats by LC-MS/MS: absolute bioavailability and dose proportionality. RSC Adv. 2017;7:9057-9063. https://doi.org/10.1039/C6RA28237G
[22] Jiang WL, Chen XG, Qu GW, Yue XD, Zhu HB, Tian JW, Fu FH. Rosmarinic acid protects against experimental sepsis by inhibiting proinflammatory factor release and ameliorating hemodynamics. Shock. 2009;32(6):608-613. https://doi.org/10.1097/SHK.0b013e3181a48e86
[23] Patton J, Byron P. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6:67–74. https://doi.org/10.1038/nrd2153
[24] Li C, Liu S, Luo G, Wang G, Zhang B, Nie Q. Comparison of plasma pharmacokinetics of Tanreqing solution between intratracheal aerosolization and intravenous injection in rats. Biomed Chromatogr. 2017;32(3). https://doi.org/10.1002/bmc.4116
[25] Ding Y, Cao Z, Cao L, Ding G, Wang Z, Xiao W. Antiviral activity of chlorogenic acid against influenza A (H1N1/H3N2) virus and its inhibition of neuraminidase. Sci Rep. 2017;7:45723. https://doi.org/10.1038/srep45723
[26] String. (2025). https://string-db.org/ (accessed on 03 January 2025)
[27] Venny. (2025). https://bioinfogp.cnb.csic.es/tools/venny/ (accessed on 03 January 2025)
[28] PubChem. (2025). https://pubchem.ncbi.nlm.nih.gov/ (accessed on 03 January 2025)
[29] Protein Data Bank. (2025). https://www.rcsb.org/ (accessed on 03 January 2025)
[30] UCSF Chimera. (2025). https://www.cgl.ucsf.edu/chimera/download.html (accessed on 03 January 2025)
[31] Biovia Discovery Studio. (2025). https://discover.3ds.com/discovery-studio-visualizer-download (accessed on 03 January 2025)
[32] SwissADME. (2025). http://www.swissadme.ch/ (accessed on 03 January 2025)
[33] pkCSM. (2025). https://biosig.lab.uq.edu.au/pkcsm/ (accessed on 03 January 2025)
[34] ProTox. (2025). https://tox.charite.de/protox3/index.php?site=home (accessed on 03 January 2025)

Details

Primary Language

English

Subjects

Pharmaceutical Botany

Journal Section

Research Article

Authors

Merve Aras
0000-0001-7047-2597
Türkiye

Özlem Yayıntaş ^*
0000-0002-3554-1881
Türkiye

Publication Date

January 11, 2026

Submission Date

February 24, 2025

Acceptance Date

March 31, 2025

Published in Issue

Year 2026 Volume: 30 Number: 1

DOI

https://doi.org/10.12991/jrespharm.1645818

IZ

https://izlik.org/JA99WW35ZT

Cite

RIS / Bibtex

APA

Aras, M., & Yayıntaş, Ö. (2026). Computational Screening of Marchantia polymorpha Against KRAS G12C Mutation in Non-Small Cell Lung Cancer. Journal of Research in Pharmacy, 30(1), 39-50. https://doi.org/10.12991/jrespharm.1645818

AMA

1.Aras M, Yayıntaş Ö. Computational Screening of Marchantia polymorpha Against KRAS G12C Mutation in Non-Small Cell Lung Cancer. J. Res. Pharm. 2026;30(1):39-50. doi:10.12991/jrespharm.1645818

Chicago

Aras, Merve, and Özlem Yayıntaş. 2026. “Computational Screening of Marchantia Polymorpha Against KRAS G12C Mutation in Non-Small Cell Lung Cancer”. Journal of Research in Pharmacy 30 (1): 39-50. https://doi.org/10.12991/jrespharm.1645818.

EndNote

Aras M, Yayıntaş Ö (January 1, 2026) Computational Screening of Marchantia polymorpha Against KRAS G12C Mutation in Non-Small Cell Lung Cancer. Journal of Research in Pharmacy 30 1 39–50.

IEEE

[1]M. Aras and Ö. Yayıntaş, “Computational Screening of Marchantia polymorpha Against KRAS G12C Mutation in Non-Small Cell Lung Cancer”, J. Res. Pharm., vol. 30, no. 1, pp. 39–50, Jan. 2026, doi: 10.12991/jrespharm.1645818.

ISNAD

Aras, Merve - Yayıntaş, Özlem. “Computational Screening of Marchantia Polymorpha Against KRAS G12C Mutation in Non-Small Cell Lung Cancer”. Journal of Research in Pharmacy 30/1 (January 1, 2026): 39-50. https://doi.org/10.12991/jrespharm.1645818.

JAMA

1.Aras M, Yayıntaş Ö. Computational Screening of Marchantia polymorpha Against KRAS G12C Mutation in Non-Small Cell Lung Cancer. J. Res. Pharm. 2026;30:39–50.

MLA

Aras, Merve, and Özlem Yayıntaş. “Computational Screening of Marchantia Polymorpha Against KRAS G12C Mutation in Non-Small Cell Lung Cancer”. Journal of Research in Pharmacy, vol. 30, no. 1, Jan. 2026, pp. 39-50, doi:10.12991/jrespharm.1645818.

Vancouver

1.Merve Aras, Özlem Yayıntaş. Computational Screening of Marchantia polymorpha Against KRAS G12C Mutation in Non-Small Cell Lung Cancer. J. Res. Pharm. 2026 Jan. 1;30(1):39-50. doi:10.12991/jrespharm.1645818